NEWS LATEST WEBCAST FINANCIAL REPORTS FINANCIAL PRESENTATIONS SHAREHOLDERS FINANCIAL DATA IR POLICY & CONTACT ARTICLES OF ASSOCIATION CORPORATE GOVERNANCE FINANCIAL CALENDAR

Notification of trade (06.09.10)

Mr. Hallvard Muri, President & CEO in Aker BioMarine ASA, has today through his company ACCA AS purchesed 500.000 shares at an average of NOK 1,7036 per share. Following this transaction Mr. Muri owns 500.000 shares in Aker BioMarine ASA.

Proposed rights issue in Aker BioMarine (03.09.10)

The Board of Directors has resolved to propose a rights issue to finance Aker BioMarine ASA’s (“Aker BioMarine”) participation in the joint venture with Lindsay Goldberg LLC and the joint venture’s acquisition of Epax Holding AS from Austevoll Seafood ASA (cf. the separate notices from Aker BioMarine of today). The proposal will be presented to Aker BioMarine’s extraordinary general meeting on 24 September 2010.

Trygg Pharma acquires Epax from Austevoll Seafood (03.09.10)

Trygg Pharma AS – a company that will be jointly owned by Aker BioMarine ASA and an affiliate of Lindsay Goldberg LLC through a newly established joint venture company (cf. the separate notice of today) – has entered into an agreement to acquire 100% of the shares in Epax Holding AS (together with its subsidiaries “Epax”), a wholly owned subsidiary of Austevoll Seafood ASA. Epax is the world’s premier high concentrate omega-3 supplement manufacturer. Epax employs a total of 74 people.

Aker BioMarine and Lindsay Goldberg to form 50/50 joint venture (03.09.10)

An affiliate of Lindsay Goldberg LLC (“LG” or “Lindsay Goldberg”) – a New York-based private investment firm with approximately USD 10 billion of equity capital under management and a long-term investment horizon of up to 20 years – has entered into an agreement with Aker BioMarine ASA (“AKBM” or “Aker BioMarine”) to acquire 50% of all outstanding shares in a newly established joint venture company (“NewCo”) that will own Trygg Pharma AS and Natural Nutrition Development Ltd AS (“NND”), both wholly owned subsidiaries of Aker BioMarine. Lindsay Goldberg will pay up to NOK 280 million for the 50% stake in NewCo, of which NOK 140 million is paid upfront and another NOK 140 million is subject to certain development milestones.

Strong Superba™ Krill sales growth (06.08.10)

The growth continued for Aker BioMarine in the second quarter of 2010. Sales growth was strong, harvesting and production were good, and the Aker BioMarine Group recorded its first-ever EBITDA in the black. The Marine Stewardship Council (MSC) certification confirms that Aker BioMarine conducts sustainable krill harvesting.

For more information, please look at Aker BioMarine‘s Q2 2010 report and presentation.

Presentation of Q2 2010 results (30.07.10)

Aker BioMarine ASA will release its interim report for the 2th quarter 2010 on August 6, 2010. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its 2th quarter 2010 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Notification of trade (20.07.10)

Aker Capital AS has renewed a total return swap with 20,200,171 underlying shares in Aker BioMarine ASA. Close is 20 October 2010. Strike NOK 1.5219 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 75,068,382 shares in Aker BioMarine ASA, i.e. 83.3%.

Certified by the Marine Stewardship Council (MSC) (25.05.10)

Aker BioMarine has today received confirmation that its krill fisheries will be certified by the Marine Stewardship Council (MSC), an independent, global, non-profit organization that works to promote the best choices in sustainable seafood. In future purchases of Aker BioMarine’s SuperbaTM and QrillTM products, consumers can be assured that their Omega-3 rich krill products are harvested in an environmentally sustainable way.

Completion of share issue and refinancing (11.05.10)

Reference is made to the stock exchange notice published earlier today regarding the register of the new share capital in Aker BioMarine ASA. The rights offering in Aker BioMarine is now completed and the company has finalized the refinancing plan communicated in the stock exchange notices on February 8 2010 and March 10 2010.

New share capital registered (11.05.10)

Reference is made to the stock exchange notice of May 5 2010. The new shares issued in the rights offering in Aker BioMarine are now registered in the Register of Business Enterprises. The share capital is now NOK 728 112 121 with a total number of shares of 728 112 121, each with par value NOK 1.00.

It is expected that the new shares will be registered on each subscribers VPS account on or about May 11 2010, and that the new shares will be tradable on the Oslo Stock Exchange from today May 11 2010.

NOTIFIABLE TRADE (05.05.10)

Reference is made to the rights offering in Aker BioMarine which was approved by the annual general meeting on April 8 2010. The following primary insiders have been allocated new shares in accordance with the allocation principles described in the prospectus dated April 14 2010.

AKBM – Final results of the rights offering (05.05.10)

Reference is made to the notice to the stock exchange dated 30 April 2010. The allocation from the rights offering, which closed on 29 April 2010 at 17:30 has been concluded by the Board of Aker BioMarine ASA on 5 May 2010.

Notification of trade | Aker Capital AS (05.05.10)

Aker Capital AS, a wholly owned subsidiary of Aker ASA, has today entered into a total return swap with cash settlement on 17,700,171 underlying shares in Aker BioMarine ASA. Close is 20 July 2010 and strike NOK 1.0107 per share. Aker Capital AS has previously entered into a total return swap on 2,500,000 shares in Aker BioMarine ASA. Close is 20 July 2010 and strike NOK 3.2941 per share. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 606,557,677 shares in Aker BioMarine ASA, i.e., 83.3% of the outstanding shares.

Notification of trade | Aker Seafoods Holding AS (05.05.10)

With reference to the share issue of Aker BioMarine ASA, which was approved by the general assembly on 8 April 2010, Aker Seafoods Holding AS has been allocated shares for exercised subscription rights according to the principles set out in the prospectus.

Aker Seafoods Holding AS subscribed for 531,489,295 new shares at a subscription price of NOK 1 per share and has been allocated 531,489,295 shares. Following completion of the rights offering, Aker Seafoods Holding AS will own a total of 606,557,677 shares, i.e., 83.3% of the outstanding shares.

Preliminary results show that the rights offering was over-subscribed (30.04.10)

Reference is made to the prospectus dated 14 April 2010 in relation to the rights offering of minimum 586,000,000 shares and up to 638,000,000 offered shares in Aker BioMarine ASA at subscription price NOK 1.00 per share.

NOTIFIABLE TRADE (27.04.10)

Mr. Tore Heldrup Rasmussen, board member in Aker BioMarine ASA, has today, through his company Heldrup AS, exercised 341 018 subscription rights and subscribed for 341 018 new shares in Aker BioMarine ASA at a subscription price of NOK 1 per new share. Heldrup AS currently owns 48 166 shares, but will own 389 184 shares subject to completion of the share issue.

Notifiable trade – Aker Seafoods Holding AS (27.04.10)

Aker Seafoods Holding AS owns 75,068,382 shares in Aker BioMarine ASA, which amounts to 83.31% of all outstanding shares in the company. Aker ASA controls 100% of Aker Seafoods Holding AS.

Notification of trade (21.04.10)

Aker Capital AS has renewed a total return swap with 2,500,00 underlying shares in Aker BioMarine ASA. Close is 20 July 2010. Strike NOK 3.2941 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 75,068,382 shares in Aker BioMarine ASA, i.e. 83.3%.

Positive development throughout the value chain from harvesting to customer (20.04.10)

Aker BioMarine continued to advance in the first quarter of 2010 with revenue growth, good harvesting, and profit growth compared with the first quarter of 2009. Sales of Superba™ Krill were 27.9 metric tons (MT) in the first quarter of 2010; sales of the company’s high-value feed ingredient Qrill™ totaled 1,865 MT, up 60 percent from the corresponding first-quarter 2009 figure. Aker BioMarine produced 4,256 MT of Qrill™ in the quarter, up 146 percent from 1,729 MT in the first quarter of 2009.

For more information, please look at Aker BioMarine’s Q1 2010 report and presentation.

Presentation of Q1 2010 results (13.04.10)

Aker BioMarine ASA will release its interim report for the 1th quarter 2010 on April 20, 2010. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its 1th quarter 2010 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Ex subscription rights 9 April (09.04.10)

The shares in Aker BioMarine ASA will be traded ex subscription rights as of today 9 April 2010.

See announcement from Aker BioMarine ASA 8 April 2010

For further information, please contact:
Hallvard Muri, president and CEO, Aker BioMarine, tel +47 24 13 00 00
Fredrik Nygaard, CFO and IR contact, Aker BioMarine, tel +47 24 13 00 00

Breakthrough for Superba™ Krill in Europe (08.04.10)

Aker BioMarine has today signed a major agreement with a leading European manufacturer and brand of dietary supplements. In the five year agreement Aker BioMarine will be the exclusive supplier of Superba™ Krill to the customer. The customer will formulate Superba™ Krill oil into one of its existing products and thus will purchase significant volumes immediately.

Last trading day inclusive subscription rights (08.04.10)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN

Reference is made to today’s stock exchange release regarding the approval of the rights offering by the general meeting of Aker BioMarine ASA. The shares in Aker BioMarine ASA will as of tomorrow, 9 April 2010, be traded exclusive subscription rights to participate in the rights offering adopted in today’s general meeting.

Annual General Meeting (08.04.10)

Aker BioMarine ASA has today on 8 April 2010 held its Annual General Meeting. All proposals to the Annual General Meeting were approved, including the rights offering in Aker BioMarine as proposed by the board of directors.

The rights offering as proposed by the board of directors is described in the stock exchange notice dated 15 March 2010. Further information will be made available in a prospectus that is expected to be published on 15 April 2010.

Norwegian and English copies of the minutes of the meeting are attached. Please also find attached the presentation held at the Annual General Meeting.

Nomination Committee Recommendations (26.03.10)

Enclosed please find recommendations from Aker BioMarine ASA’s Nomination committee and presentation of the Board of Directors in connection with the company’s Annual General Meeting on 8 April 2010.

Aker BioMarine increases loan facility from majority owner (26.03.10)

Aker BioMarine and Aker ASA have today agreed to increase the short term loan facility announced September 15 with NOK 20 million. Since the loan agreement was entered into in September, Aker BioMarine has had a positive development with increased sales and a good start to fishing season. However, this has led to increased working capital financing need.

Change in announcement date for the first quarter 2010 financial results (18.03.10)

The company has decided to change the announcement date for the first quarter 2010 financial results to April 20 2010. The original announcement date was April 28 2010.

Notice of Annual General Meeting (18.03.10)

The shareholders in Aker BioMarine ASA are invited to attend the Annual General Meeting to be held on Thursday 8 April 2010 at 08.00 hrs at Felix Conference Centre, Bryggetorget 3, Aker Brygge, Oslo, Norway.

Please find attached a Notice of Annual General Meeting in Aker BioMarine ASA, the attendance ballot and the Annual Report 2009.

The notice of the annual general meeting with all relevant documents attached, including a print version of the 2009 annual report, will be posted to all shareholders on March 18.

The Nomination Committee recommendations will be made public through a press release and a notification to the Oslo Stock Exchange as soon as they are finalized.

Superba™ Krill med full sporbarhet fra fangst til forbruker (17.03.10)

I lys av oppslag i pressen rundt sporbarhet av omega-3 og spesielt fiskeoljer fra omstridte fiskerier i Vest-Sahara og Marokko vil Aker BioMarine klargjøre status for våre produkter og sporbarhetssystem.

Proposed Conditions for Share Issue (15.03.10)

NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR TO, JURISDICTIONS IN WHICH THE SHARE OFFERING IS PROHIBITED, INCLUDING USA, AUSTRALIA, CANADA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, JAPAN OR HONG KONG.

Understanding reached with bondholders (10.03.10)

Aker BioMarine has negotiated a solution with its bondholders to refinance the company’s NOK 750 million bond loan, which matures in May 2010. As previously announced, Aker will convert into equity its net receivables that are payable by Aker BioMarine, while the other bondholders have accepted a three-year extension of the loan’s maturity date for the remaining NOK 305 million of the loan in return for a 0.25 percentage point increase in the loan interest they will receive, provided that Aker issue a payment guarantee.

Aker BioMarine refinancing plan (08.02.10)

Aker BioMarine and its majority shareholder and largest creditor, Aker ASA, have prepared a refinancing plan for the company. The plan establishes a solid financial foundation for advancing Aker BioMarine’s business activities. The company is in discussions with key bondholders to secure their approval of the refinancing plan.

Aker BioMarine ASA Q4 2009 presentation (08.02.10)

Aker BioMarine continued its advances in the fourth quarter of 2009 with revenue growth and improved cash flow from operations. 24.8 metric tons (MT) of Superba™ Krill was sold in the fourth quarter; up 48 percent from the third quarter. Sales of the high-value feed ingredient Qrill™ grew 57 percent compared with the fourth quarter of 2008; the figure is down slightly from the third quarter of 2009.

For more information, please look at Aker BioMarine’s Q4 2009 report and presentation.

Presentation of Q4 2009 results (01.02.10)

Aker BioMarine ASA will release its interim report for the 4th quarter 2009 on February 8, 2010. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its 4th quarter 2009 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Neptune’s European krill composition patent revoked by the European Patent Office (15.12.09)

Neptune Technologies & Bioressources Inc’s (‘Neptune’) European Patent EP1417211B1 has been opposed by Aker BioMarine and the Israeli company Enzymotec. The filed oppositions were dealt with by the European Patent Office (‘EPO’) in a hearing in Munich on December 14th. EPO’s opposition division concluded the hearing to revoke Neptune’s European patent on the basis of insufficiency of disclosure.

Meldepliktig handel (14.12.09)

Aker Seafoods Holding AS har kjøpt 60.000 aksjer i Aker BioMarine ASA til kurs 9,73. Ny beholding er 75.068.382 aksjer, dvs. 83,31 % av totalt antall aksjer i Aker BioMarine.

Aker Capital AS har en total return swap med eksponering mot 2.500.000 aksjer i Aker BioMarine ASA. Forfall 20. januar 2010 Avregningskurs er 6, 991 pr. aksje.

Aker BioMarine awarded public grant for research on Superba™ Krill (10.12.09)

Aker BioMarine has been awarded a three-year NOK 8 million research grant from the Research Council of Norway’s Food Programme. The biotechnology company will use the funds to continue its ambitious documentation program on Superba™ Krill products. Aker BioMarine was one of five receivers out of an application pool of 37 companies.

Superba™ Krill Oil ready for the European market (10.12.09)

Aker BioMarine has been notified by the Finnish Food Safety Authority that Superba™ Krill Oil is now approved as Novel Food in the European Union. Consequently, Superba™ Krill Oil can be sold in all countries within the European Union.

Valensa International will use Superba™ Krill Oil for Joint Health and Eye Health products (08.12.09)

Norwegian biotechnology company Aker BioMarine has signed a long-term global supply agreement with Valensa International for the use of Superba™ in Krill Oil Joint Health and Eye Health products where Aker BioMarine will be the exclusive supplier of krill oil. Under the agreement, Aker BioMarine and Valensa will also jointly perform clinical studies to document the unique properties of Superba™ Krill Oil as an ingredient in Valensa’s patented and patent-pending formulations.

Ready to face Neptune in court (16.11.09)

Neptune Technologies & Bioresources, Inc. has sent out a press release saying that they have filed a patent infringement lawsuit against Aker BioMarine and its distributor Jedwards International in the U.S. District Court for the District of Massachusetts. In the press release, Neptune claims infringement of U.S. Patent No. 6,800,299.

Meldepliktig handel (30.10.09)

Aker Seafoods Holding AS har i dag kjøpt 350.889 aksjer i Aker BioMarine ASA til kurs 7,16. Selger er Aker Seafoods ASA. Ny beholding er 75.008.382 aksjer, dvs. 83,24 % av totalt antall aksjer i Aker BioMarine.

Aker Capital AS har en total return swap med eksponering mot 2.500.000 aksjer i Aker BioMarine ASA. Forfall 20. januar 2010. Avregningskurs er 6, 991 pr. aksje.

Aker BioMarine third quarter 2009 (28.10.09)

Aker BioMarine continued to advance in the third quarter of 2009, with strong Superba™ Krill sales growth and improved cash flow from operations. Sales of Superba™ Krill in third quarter was 16.8 metric tons (MT) which is 236 percent higher than second quarter. Sales of the high-value Qrill™ feed ingredient also rose sharply in the third quarter. Sales increased by 60 percent to 2 729 MT, up from 1 701 MT in the second quarter of 2009.
For more information, please look at Aker BioMarine’s Q3 2009 report and presentation.

Aker BioMarine strengthens US market position (28.10.09)

Mercola Group in the USA has selected the biotechnology company Aker BioMarine as its exclusive supplier of krill oil for its Mercola Advanced Nutrition Antarctic Pure Krill Oil products. The agreement provides entry into an important distribution channel for dietary supplements in the United States.

Superba Krill grows in Europe (28.10.09)

Aker BioMarine is experiencing strong and growing interest for the dietary supplement Superba™ Krill in the European market. The biotechnology company has recently applied for Novel Food approval of Superba™ Krill in the EU.

Presentation of Q3 2009 results (22.10.09)

Aker BioMarine ASA will release its interim report for the third-quarter on October 28, 2009. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its third-quarter 2009 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Court victory for Superba Krill (09.10.09)

Aker BioMarine and Superba Krill won. Orkla lost its court battle to block competition from the omega-3 based dietary supplement Superba Krill.

Seier til Superba Krill (09.10.09)

Aker BioMarine og Superba Krill vant. Orkla tapte kampen om å stanse konkurransen fra det omega-3 baserte kosttilskuddet Superba Krill.

Superba™ Krill Oil – beneficial effect on cholesterol (21.09.09)

A new study performed for the biotechnology company Aker BioMarine has demonstrated that Superba™ Krill Oil might be of benefit in individuals with metabolic syndrome and fatty liver. These results are important because they confirm previous findings.

Overraskende anklager fra markedsleder (17.09.09)

En større markedsføringskampanje for Aker BioMarines Superba™ Krill pågår for tiden i norske medier. Orkla-konsernet ved Axellus AS (tidligere Peter Møller AS) har i denne forbindelse begjært midlertidig forføyning med krav om midlertidig stans i markedsføringen av Superba™ Krill.

Ski champion Ole Einar Bjørndalen teams with Superba™ Krill (17.09.09)

The biotechnology company Aker BioMarine and the biathlon champion, Ole Einar Bjørndalen have signed a long-term cooperation agreement. Aker BioMarine’s Superba™ Krill brand is now a personal sponsor of the athlete who has won more competitions than any other skier.

Aker BioMarine borrows from majority owner (17.09.09)

The biotechnology company Aker BioMarine will borrow up to NOK 90 million from the company’s majority shareholder, Aker ASA. Up to NOK 50 million of the aforesaid loan can be drawn initially. Additional NOK 40 million will be made available once Aker BioMarine has presented and received Aker ASA’s approval of a comprehensive refinancing plan. The new loan will be secured by major company assets.

Exclusive Superba™ agreement in USA (02.09.09)

The biotechnology company Aker BioMarine has signed an agreement to be the exclusive supplier of the company’s Superba™ Krill Oil dietary supplement to the market leader Schiff Nutrition International. The agreement is a major breakthrough for Aker BioMarine in the US market.

Superba™ Krill direct sales to consumers in Norway (31.08.09)

Aker BioMarine is launching its new Superba™ Krill Concentrate dietary supplement on 1 September. The dietary supplement will be launched via a nationwide campaign in several media channels.

Notification of trade (21.08.09)

Aker Capital AS has renewed a total return swap with 2,500,00 underlying shares in Aker BioMarine ASA. Close is 20 October 2009. Strike NOK 6.2983 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 74,657,494 shares in Aker BioMarine ASA, i.e. 82.9%.

Solid start in USA for Superba Krill (11.08.09)

The biotechnology company Aker BioMarine shipped 15 metric tons (MT) of Superba Krill to the US market in the second quarter of 2009. Of this tonnage, 4.8 MT were sales recorded in the second quarter.

New Aker BioMarine Group EVP (10.08.09)

Matts Johansen (32) has been appointed new Group EVP in charge of sales and marketing of the biotechnology company Aker BioMarine. Mr. Johansen will join Aker BioMarine this fall.

Presentation of Q2 2009 results (04.08.09)

Aker BioMarine ASA will release its interim report for the second-quarter on August 11, 2009. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its second-quarter 2009 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Superba Krill Oil better than fish oil (30.06.09)

The nutraceutical Superba Krill Oil, rich in omega-3 phospholipids, gives substantially more reduction of fat in the heart and the liver than omega-3 from fish oil. This is demonstrated in a new preclinical study performed for the biotechnological company Aker BioMarine.

Aker BioMarine strengthens organization (11.06.09)

The biotechnology company Aker BioMarine is strengthening finance, and pharmaceutical-market operations.

Superba — on its way to global markets (05.05.09)

Aker BioMarine’s Superba™ Krill Oil was the best-selling omega-3 product in Norwegian health food stores in the first quarter of 2009, according to statistics from the health food wholesaler Macronova. Now, this unique dietary supplement product is on its way to international markets.

Presentation of Q1 2009 results (28.04.09)

Aker BioMarine ASA will release its interim report for the first-quarter on May 5, 2009. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its first-quarter 2009 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Notification of trade (21.04.09)

Aker Capital AS has renewed a total return swap with 2,500,00 underlying shares in Aker BioMarine ASA. Close is 20 July 2009. Strike NOK 4.8073 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 74,657,494 shares in Aker BioMarine ASA, i.e. 82.9%.

Updated financial calendar for 2009 (16.04.09)

Aker BioMarine have modified the previously announced time and date for publication of first-quarter 2009 report. New date as follows:

5 May 2009 (rescheduled from 29 April)

Annual General Meeting (02.04.09)

Aker BioMarine ASA has today on 2 April 2009 held its Annual General Meeting. All proposals to the AGM were approved.

An Norwegian and English copy of the minutes of the meeting are attached. Please also find the presentation attached.

Nomination Committee Recommendations (27.03.09)

Enclosed please find recommendations from Aker BioMarine ASA’s Nomination committee in connection with the company’s Annual General Meeting on 2 April 2009.

AKBM Recommendations
AKBM CV

Notice of Annual General Meeting (19.03.09)

The shareholders in Aker BioMarine ASA are invited to attend the Annual General Meeting to be held on Thursday 2 April 2009 at 11.00 hrs at Felix Conference Centre, Bryggetorget 3, Aker Brygge, Oslo, Norway.

Preliminary notice of Aker BioMarine ASA annual general meeting (13.03.09)

Please see attached preliminary notice of annual general meeting for Aker BioMarine ASA, attendance ballot and annual report for 2008. The notice of the annual general meeting and attachments will be sent to all shareholders with an known address separately on 19 March 2009.

Annual information 2008 (12.03.09)

Issuers of listed transferable securities are required to provide Oslo Stock Exchange with an annual statement of information made available to the public, cf the Stock Exchange Regulations, section 5-2 fifth paragraph. Attached is an annual overview for Aker BioMarine ASA for the period 12 March 2008 - 11 March 2009.

Superba Krill off to promising start (13.02.09)

The biotechnology company Aker BioMarine is experiencing strong and growing interest in Superba Krill Oil. In January 2009 the dietary supplement was the best-selling omega-3 product in Norwegian health food shops.

Presentation of 4Q 2008 results (06.02.09)

Aker BioMarine ASA will release its interim report for the fourh quarter on February 13, 2009. On the day of the release, representatives of the company will present the results at

Jostein Dalland to leave Aker BioMarine (27.01.09)

The biotechnology company Aker BioMarine has begun the search for a successor to Jostein Dalland, Group EVP, Sales and Marketing. Mr. Dalland has decided to leave Aker BioMarine for personal reasons.

Hallvard Muri new CEO of Aker BioMarine (09.01.09)

Hallvard Muri (48) has been appointed president and chief executive officer of Aker BioMarine ASA. He takes over from Kjell Inge Røkke, who has led the biotechnology company since August 2008.

Aker buys the Antarctic Navigator (22.12.08)

The Board of Aker ASA has approved the agreement from September this year to buy the vessel the Antarctic Navigator. The purchase price is NOK 550 million, as previously communicated.

Completion of acquisition of shares in Aker Ocean Harvest AS (08.12.08)

Reference is made to stock exchange announcement dated 3 December 2008 regarding Aker Seafoods Holding AS’ acquisition of the existing shares in Aker Ocean Harvest AS. Aker Seafoods Holding AS’ acquisition of the existing shares in Aker Ocean Harvest AS has now been completed.

For further information please contact:
EVP & Partner Geir Arne Drangeid, Aker, tel. + 47 24 13 00 65
EVP & CFO Aaron Kramer, Aker BioMarine, tel. + 47 916 30 130

Extraordinary general meeting (04.12.08)

Aker BioMarine ASA has today, on 4 December 2008, held an extraordinary general meeting. All items on the agenda were resolved by the general meeting in accordance with the notice for the meeting, and the agreement regarding the sale of the existing shares of Aker Ocean Harvest AS was approved by the general meeting.

Please find attached minutes from the meeting in Norwegian and English.

For further information please contact:
EVP & Partner Geir Arne Drangeid, Aker, tel. + 47 24 13 00 65
EVP & CFO Aaron Kramer, Aker BioMarine, tel. + 47 916 30 130

Result of offering of shares in Aker Ocean Harvest AS (03.12.08)

Reference is made to previous stock exchange announcements regarding the offering of shares in Aker Ocean Harvest AS.

The offer period for the offering expired at 17:30 hours, CET, on 2 December 2008.

The conditions for completion of the offering have not been met, and the 9,011,212 existing shares in Aker Ocean Harvest AS will thus be acquired by Aker Seafoods Holding AS at NOK 22.58 per existing share pursuant to the terms and conditions of the offering.

Arctic Securities ASA has been the manager for the offering.

For further information please contact:
EVP & Partner Geir Arne Drangeid, Aker, tel. + 47 913 10 458
EVP & CFO Aaron Kramer, Aker BioMarine, tel. + 47 916 30 130

Unique pre-clinical results on Superba™ Krill Oil (19.11.08)

Aker BioMarine has performed four animal studies in mice and rats with SuperbaTM. To investigate the beneficial effects of SuperbaTM three different models has been used for this purpose:
A) High fat fed mice – a diet-induced obesity model – 2 studies
B) Zucker rats – a genetic obesity model – 1 study
C) Effects on collagen-induced arthritis in mice – 1 study

Publication of information memorandum for Aker BioMarine (19.11.08)

Reference is made to previous stock exchange announcements. Please find attached an information memorandum prepared pursuant to section 3.5 of the continuing obligations for companies listed on Oslo Børs and in connection with (i) the offering of shares in Aker Ocean Harvest AS to existing shareholders of Aker BioMarine, and (ii) the sale of the vessel Antarctic Navigator to Aker ASA.

For further information please contact:
EVP & Partner Geir Arne Drangeid, Aker, tel. + 47 913 10 458
EVP & CFO Aaron Kramer, Aker BioMarine, tel. + 47 916 30 130

Offering of shares in Aker Ocean Harvest AS (19.11.08)

Reference is made to previous stock exchange announcements on the planned offering of shares in Aker Ocean Harvest AS. Oslo Børs has approved the prospectus for the offering of shares in Aker Ocean Harvest AS.

AKBM - Extraordinary Shareholders Meeting of Aker BioMarine ASA (13.11.08)

The shareholders in Aker BioMarine ASA are invited to attend the Extraordinary General Meeting to be held on Thursday 4 December 2008 at 10.00 hrs at Felix Conference Centre, Bryggetorget 3, Aker Brygge, Oslo, Norway, in order to consider the approval of the agreement regarding the sale of the shares of Aker Ocean Harvest AS.

Strong foundation for focused development (13.11.08)

Aker BioMarine continues its development through intensified focus on core activities. In the third quarter of 2008, the company implemented an action plan, streamlined the organization to focus on its core expertise in sustainable harvesting of Antarctic krill and the production of high-value bioactive products, and advanced its documentation, sales and marketing efforts.

Information on allocation rights to shares in Aker Ocean Harvest (12.11.08)

The board of directors of Aker BioMarine ASA have today resolved to transfer the fisheries business of the group in Argentine and on the Faroe Islands to Aker Ocean Harvest AS. The shareholders of Aker BioMarine will be offered shares in the newly established company Aker Ocean Harvest AS.

Aker BioMarine sells fisheries operations (12.11.08)

The board of directors of Aker BioMarine ASA has today resolved to transfer the fisheries business of the group in Argentine and on the Faroe Islands to Aker Ocean Harvest AS. The shareholders of Aker BioMarine will be offered shares in the newly established company Aker Ocean Harvest AS.

Presentation of 3Q 2008 results (03.11.08)

Aker BioMarine ASA will release its interim report for the third quarter on November 13, 2008. On the day of the release, representatives of the company will present the results at

Hotel Continental, Bankett & Konferanseavdeling, Stortingsgaten 24/26, Oslo. The presentation begins at 08.30 a.m.

CFO and Executive Vice President Aaron Kramer will give you an updating from the company.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its third-quarter 2008 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Sustainability of operations (27.10.08)

Aker BioMarine has successfully passed a pre-assessment for Marine Stewardship Council (MSC) certification of its sustainable operations. The company will now proceed for full MSC assessment.

Aker BioMarine applies for MSC certification for its Antarctic krill operations (13.10.08)

Aker BioMarine has successfully completed a pre-assessment for Marine Stewardship Council (MSC) accreditation of its Antarctic krill fishing operations. The company will now proceed to a full MSC assessment.

Breakthrough for new production solution (17.09.08)

Aker BioMarine has found a new solution for cost-effective production of a new nutritional health ingredient for human consumption. The breakthrough is presented today at the company’s capital markets day.

Aker BioMarine capital markets day (10.09.08)

Aker BioMarine is holding its capital markets day on Wednesday September 17 at 0930 CET in the Felix conference centre at Aker Brygge in Oslo.

The company’s chairman Leif-Arne Langøy, chief executive Kjell Inge Røkke and other key personnel from Aker BioMarine will be present at the meeting.

Presentations will be given to analysts, investors and other interested parties who register for the event. For practical reasons, we kindly ask all attendees to register participation via e-mail to merete.kildahl@akerbiomarine.com by 1600 CET on Monday September 15.

For further information please contact:
Geir Arne Drangeid, Senior partner and EVP Aker AS, tel. +47 913 10 458
Aaron Kramer, CFO and IR manager, tel. + 47 916 30 130

Sharper focus on krill (04.09.08)

The biotechnology company Aker BioMarine continues to focus on its core business, krill harvesting and processing, and is de-emphasizing activities associated with concentrated fish oils.

Group management changes (27.08.08)

The biotechnology company Aker BioMarine has modified its management team. Aaron Kramer is the company’s new Chief Financial Officer. Prior to appointment as CFO, Mr. Kramer was EVP in charge of business development and strategy.

Helge Midttun leaves Aker BioMarine (20.08.08)

Helge Midttun is stepping down as President and CEO of Aker BioMarine, effective today. Kjell Inge Røkke will for the coming period take charge of leading the company, which is 82.9 per cent owned by Aker.

Notification of trade (19.08.08)

Aker Capital AS has renewed a total return swap with 1,669,906 underlying shares in Aker BioMarine ASA. Close is 20 October 2008. Strike NOK 16.7209 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 74,657,493 shares in Aker BioMarine ASA, i.e. 82.9%.

Meldepliktig Handel (12.08.08)

Helle Kruse Nielsen, styremedlem i Aker BioMarine ASA, kjøpte 11. august 2008, 30.000 aksjer i Aker BioMarine ASA. Aksjene er kjøpt til kurs NOK 16,00. Helle Kruse Nielsen eier etter dette 30.000 aksjer i Aker BioMarine ASA.

Meldepliktig handel (08.08.08)

Nils Brendemo, finansdirektør i Aker BioMarine ASA, har i dag 8. august 2008 kjøpt 3.000 aksjer i Aker BioMarine ASA. Aksjene er kjøpt til kurs NOK 16,00. Nils Brendemo eier etter dette 5.000 aksjer i Aker BioMarine ASA.

Superba™ production scaling up (08.08.08)

The biotechnology company Aker BioMarine is scaling up its industrial production of the high-value krill oil Superba™ as a dietary supplement. Start-up phase challenges in transitioning from small-scale manufacturing to industrial production have been solved.

Presentation of 2Q 2008 results (30.07.08)

Aker BioMarine ASA will release its interim report for the second quarter on Friday 8 August, 2008. On the day of the release, representatives of the company will present the results at

Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its second-quarter 2008 interim report to the Oslo Stock Exchange prior the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Meldepliktig handel (15.07.08)

Hogne Vik, konserndirektør i Aker BioMarine ASA, har gjennom sitt selskap ENG AS 14. juli 2008 kjøpt 4.000 aksjer i Aker BioMarine ASA. Aksjene er kjøpt til kurs NOK 14,50. Eng AS eier etter dette 44.000 aksjer i Aker BioMarine ASA.

Meldepliktig handel (08.07.08)

Hogne Vik, konserndirektør i Aker BioMarine ASA, har gjennom sitt selskap ENG AS kjøpt 10.000 aksjer i Aker BioMarine ASA. Aksjene er kjøpt til kurs NOK 15,-. Eng AS eier etter dette 40.000 aksjer i Aker BioMarine ASA.

Mandatory notification of trade (30.05.08)

Aker Seafoods Holding AS, a wholly owned subsidiary of Aker ASA, has bought 2,233,415 shares in Aker BioMarine ASA at a price of NOK 16.48 per share. New holding is 74,707,494 which represent 82.9 % of the issued share capital. Aker Capital AS, a wholly owned subsidiary of Aker ASA, holds a total return swap with 1, 669,906 underlying shares in Aker BioMarine ASA. Close is 18 August 2008.

Mandatory notification of trade (09.05.08)

Aker Seafoods Holding AS, a wholly owned subsidiary of Aker ASA, has
bought 3,692,241 shares in Aker BioMarine ASA at a price of NOK 16
per share. New holding is 72,474,079 which represent 80.4 % of the
issued share capital. Aker Capital AS, a wholly owned subsidiary of
Aker ASA, holds a total return swap with 1, 669,906 underlying shares
in Aker BioMarine ASA. Close is 18 August 2008.

Great interest in Superba™ in international markets (29.04.08)

In the first quarter of 2008, the biotechnology company Aker BioMarine introduced the high value krill-oil Superba™ in the US. Market reception has been very good.

Secures financing for growth and development (28.04.08)

The biotechnology company Aker BioMarine has secured a NOK 400 million subordinated convertible loan. The loan will provide financial clout for Aker BioMarine’s targeting of international growth markets and the company’s further development.

Presentation of 1Q 2008 results (22.04.08)

Aker BioMarine ASA will release its interim report for the first quarter on Tuesday 29 April, 2008. On the day of the release, representatives of the company will present the results at

Shippingklubben, Haakon VII’s gt. 1, 0112 Oslo. The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its first-quarter 2008 interim report to the Oslo Stock Exchange prior the the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Best regards,
Aker BioMarine ASA

Avholdt generalforsamling (03.04.08)

Aker BioMarine ASA har i dag 3. april 2008 avholdt ordinær generalforsamling. Bortsett fra agendapunkt 3 ble alle forslag vedtatt i henhold til innkallingen.

Vedlagt oversendes protokoll for generalforsamlingen på norsk og engelsk.

Nomination Committee Recommendations (17.03.08)

Enclosed please find the recommendations of Aker BioMarine ASA‘s Nomination Committee in connection with the company‘s Annual General Meeting on April 3, 2008.

The recommendations include proposals for remuneration of Board and Nomination Committee members.

For further information please contact:
Helge Midttun, CEO, Aker BioMarine, tlf 913 35 790
Nils Brendemo, CFO, Aker BioMarine, tlf 915 48 015

Valgkomitéens innstilling (17.03.08)

Vedlagt følger innstilling fra Aker BioMarine ASAs valgkomité i forbindelse med selskapets ordinære generalforsamling 3. april 2008.

Innstillingen omfatter forslag til honorarer til medlemmene av selskapets styre og valgkomité.

For nærmere informasjon, vennligst kontakt:
Konsernsjef Helge Midttun, Aker BioMarine, tlf 913 35 790
Finansdirektør Nils Brendemo, Aker BioMarine, tlf 915 48 015

Financing of ambitious plans (14.03.08)

The Board of Directors of the biotechnology company Aker BioMarine ASA asks its Annual Shareholders’ Meeting to authorise to obtain a subordinated convertible loan of up to MNOK 700. This will provide financial strength for further development of the company’s plans within international growth markets.
The request for such authorisation will be presented at the Annual Shareholders’ Meeting of Aker BioMarine on April 3, 2008.

Innkalling til ordinær generalforsamling (14.03.08)

Aksjonærene i Aker BioMarine ASA innkalles til ordinær generalforsamling torsdag 3. april 2008 kl. 10.00 på Felix konferansesenter, Bryggetorget 3, Aker Brygge, Oslo.

Notice of Annual General Meeting (14.03.08)

The shareholders in Aker BioMarine ASA are invited to attend the Annual General Meeting to be held on Thursday 3 April 2008 at 10.00 hrs at Felix Conference Centre, Bryggetorget 3, Aker Brygge, Oslo, Norway.

Annual information 2007 (13.03.08)

Issuers of listed transferable securities are required to provide
Oslo Stock Exchange with an annual statement of information made
available to the public, cf the Stock Exchange Regulations, section
5-2 fifth paragraph. Attached is an annual overview for Aker BioMarine ASA for the period 1 January 2007 - 13 March 2008

Ready for launch (15.02.08)

In 2007, the biotechnology company Aker BioMarine achieved important, broad-ranging advances throughout its value chain. Shortly, the company will launch both its dietary supplement Superba™ and Qrill™ krill oil.

Presentation of 4Q 2007 results (04.02.08)

Aker BioMarine ASA will release its interim report for the fourth quarter on Friday 15 February, 2008. On the day of the release, representatives of the company will present the results at Felix konferansesenter, Bryggetorget 3, Aker Brygge, 0250 Oslo. Meetingroom Lancing.
The presentation begins at 08.30 a.m.

All interested parties are welcome to attend. No advance registration is required.

Aker BioMarine will submit its fourth-quarter 2007 interim report to the Oslo Stock Exchange prior the the 08.30 presentation. Presentation material will be available at www.newsweb.no and www.akerbiomarine.com.

Notification of trade (24.01.08)

Aker Capital AS has bought a total return swap with 1,669,906 underlying shares in Aker BioMarine ASA. Close is 18 August 2008. Strike NOK 18.48 per share. Aker Capital is a wholly owned subsidiary of Aker ASA. Aker holds through its wholly owned subsidiary Aker Seafoods Holding AS 68,731,837 shares in Aker BioMarine ASA, i.e. 76.3%.

Advances across the value chain (01.11.07)

The biotechnology company Aker BioMarine has developed a new dietary supplement: Superba™. Market launch of Superba™ is scheduled for March 2008. In the third quarter of 2007, Aker BioMarine achieved progress across its value chain.

Aker BioMarine signs krill oil extraction agreements (29.10.07)

The biotechnology company Aker BioMarine has entered into agreements in New Zealand and France that secure production of high-value krill oil.

Aker BioMarine builds Life Science Factory (24.10.07)

The biotechnology company Aker BioMarine is converting the modern trawler Atlantic Navigator into an advanced factory for harvesting and processing health-promoting ingredients from krill.

Aker BioMarine strengthens its organization (15.10.07)

The biotechnology company Aker BioMarine is strengthening its Group management. Hogne Vik has been appointed Group EVP in charge of the Pharma business area. Sjur Tveite has been appointed Group EVP for the Aquaculture & Animal business area. Aaron Kramer is the Group’s new EVP for Strategy & Business Development.

Excellent results for Qrill (30.08.07)

Aker BioMarine’s Qrill™ krill meal demonstrates excellent aquaculture yield improvement. Salmon fed the company’s Qrill™ product weigh 18 and 23 percent more than salmon that consumed fish feed that did not contain Qrill™ — according to studies performed by AKVAFORSK, a leading Norwegian aquaculture research institution.

Aker BioMarine builds brand names (13.08.07)

Aker BioMarine continued to advance its production and sales of krill meal in the second quarter of 2007. The company is building its own brand names.

Aker BioMarine acquires Atlantic Navigator (06.07.07)

Aker BioMarine doubles its in-house production capacity for krill meal through its acquisition of the factory ship Atlantic Navigator.

Implementation of merger between Natural ASA and Aker BioMarine ASA (05.06.07)

On 29 March 2007 the merger between Natural ASA (“Natural”) and Aker BioMarine ASA (“Aker BioMarine”), both subsidiaries of Aker ASA, was approved by shareholders. Following expiry of the creditor notice period on 4 June 2007, the merger is implemented effective from today, 5 June 2007.

Two krill-licenses awarded to Aker BioMarine (31.05.07)

The Norwegian Directorate of Fisheries today announced that Aker BioMarine has been awarded two licenses for krill-fisheries in the Antarctic. The licenses are related to the vessels Saga Sea and Atlantic Navigator. Saga Sea has already been operating on a temporarily license in the Antarctic.

Aker BioMarine ahead of schedule (08.05.07)

Aker BioMarine’s first-quarter 2007 accounts show that the company is ahead of its original schedule for profit performance and efficient production of krill meal.

Bond Issue for Aker BioMarine ASA (07.05.07)

Aker BioMarine ASA to establish NOK 750 million bond loan.

Aker BioMarine ASA (AKBM) has decided to issue its first bond loan. The bond loan will have 3 years maturity with floating interest rate (3 month NIBOR + margin). The borrowing limit will be NOK 1.000 million, while the first tranche will be NOK 750 million.

Aker BioMarine makes decisive market moves (20.03.07)

Aker BioMarine is implementing measures that will enable the company to deliver own volumes of krill oil produced on board the company’s modern factory trawlers, as early as in 2009. The company is also strengthening its financial clout.

Financial statement (02.03.07)

Please find attached the Aker BioMarine’s financial statement. Profit and loss for 2006 and 2005 and the lance sheet at 31.12 are pro forma, as the Aker BioMarine Group (Natural owned 89.14 %) was formed 1 January 2005.
As announced 27 February, Aker BioMarine’s 2006 profit performance accords with the company’s business plan.

Aker BioMarine 4th quarter 2006 (01.03.07)

Please find attached the presentation material used at today‘s presentation of Aker BioMarine‘s fourth quarter results 2006.

Aker BioMarine and Natural agree to merge (27.02.07)

The boards of directors of Aker BioMarine and the biotechnology company Natural have agreed to recommend a merger of the two companies. The merged company will be called Aker BioMarine. The company will become a leader in the production of valuable, bioactive marine additives and ingredients for the food, dietary supplements, pharmaceuticals, and aquaculture industries.

Aker BioMarine on schedule (27.02.07)

Aker BioMarine’s 2006 profit performance accords with the company’s business plan. Aker BioMarine had 2006 operating revenues of NOK 460 million; operating profit before depreciation and amortization (EBITDA) amounted to NOK 26 million, according to pro forma accounts for 2006 as a whole.

Presentation of 4th quarter results for 2006 (22.02.07)

Aker ASA, Aker American Shipping ASA, Aker Floating Production ASA, Aker Drilling ASA, Aker BioMarine ASA and Aker Exploration ASA release their preliminary annual and 4th quarter results for 2006 on Thursday 1 March 20007.

Aker BioMarine ASA – Pro Forma Financial Information (11.12.06)

The following sets forth pro forma consolidated financial information for the year ended 31 December 2005 and for the three first quarters of 2006. The pro forma combined financial information has been derived from financial information in the consolidated accounts of Aker ASA and financial information from Natural ASA and Krill A/S.

Gain on the establishment of Aker BioMarine (08.12.06)

The establishment of Aker BioMarine and that company’s recently completed share issue have resulted in an approximately NOK 3.5 billion positive profit effect for Aker in the fourth quarter of 2006. The gain will be reported in Aker ASA’s accounts (parent and holding company).

Aker BioMarine – completed private placement (08.12.06)

Aker BioMarine, a subsidiary of Aker, has completed the previously announced private placement and has raised NOK 1.2 billion in new funding from Norwegian and international investors. The price per share was set at NOK 90, valuing the company at NOK 5,070 million after the placement, divided into 56 333 300 shares. Aker’s ownership following the private placement is 76.2 %.

Helge Midttun appointed as President and CEO of Aker Biomarine (26.09.06)

Aker has appointed Helge Midttun as President and CEO of its Aker BioMarine subsidiary. Aker BioMarine specializes in harvesting and processing of fish and krill into valuable products for the aquaculture and food industries, and other industrial applications.

Superba Krill
Norsk forbruker kontakt
Telefon: 815 56 333
E-post:
kundeservice @ superba.no

For international
Superba Krill enquiries:
For Europe:
E-mail
Phone: +47 24 13 00 00
For North America:
E-mail
Phone: +47 24 13 00 00